Analytica Limited’s PeriCoach® Is Now CE-Mark For Treatment Of Pelvic Organ Prolapse

  • Apr 18, 2019 AEST
  • Team Kalkine
Analytica Limited’s PeriCoach® Is Now CE-Mark For Treatment Of Pelvic Organ Prolapse

Analytica Limited (ASX: ALT) is a medical device company whose lead product is the PeriCoach™ System, an e-health treatment system for women who suffer Stress Urinary Incontinence. The company believes that PeriCoach is the only smartphone pelvic floor muscle rehabilitation system indicated for women to target resolution of symptoms for mild to moderate POP, UI and sexual wellness.

Today, the company announced that its PeriCoach system is now CE-Marked to assist in the conservative treatment of Pelvic Organ Prolapse (POP) in addition to urinary incontinence (UI), allowing PeriCoach to be sold in the European Economic Area, Switzerland and Turkey for the conservative treatment of pelvic organ prolapse.

As per the company’s Chairman Dr. Michael Monsour, expanding the indication of PeriCoach to include pelvic organ prolapse supports the company’s commitment to offering women and clinicians the best in class conservative treatment tool for pelvic floor disorders including urinary incontinence and sexual wellness.

The PeriCoach system assists women to properly perform pelvic floor exercises and it is widely recognised that pelvic floor muscle exercises are an effective tool in reducing the burdensome POP symptoms. It is believed that Pelvic floor muscle exercises hare an effective tool in treating women with mild to moderate POP symptoms. In a 2015 case study, the company had demonstrated that when the PeriCoach was used in coordination with a pelvic floor physiotherapist, symptoms of POP were reduced, quality of life improvements were reported, and the requirement of an assistive inserted pessary was no longer needed.

In the US alone, around 60 Million women are experiencing POP, urinary incontinence and sexual wellness concerns. As the population ages, more women are at risk for surgery which is leaving room for complications and a large burden on healthcare systems.

For the 6 months ended December 2018, the company reported revenue from ordinary activities of $33,164, down by 28% on the previous corresponding period (pcp). Further, the company reported a net loss of $1,478,882, down by 15% on pcp.

In the US, the company has FDA approval both for the sale of the PeriCoach via the prescription model as favoured by the medical device companies and over the counter FDA approval for direct sale to consumer as favoured by the IT companies.

Now, let’s have a glance at the company’s stock performance and the return it has posted over the past few months. The stock traded at a price of $0.004 during the day’s trade with a market capitalisation of ~$13.35 million as on 18 April 2019. The counter opened the day at $0.004 and reached the day’s high of $0.004 and touched a day’s low of $0.004 with a daily volume of ~ 202,989. The stock has provided a year till date return of -10.00% & also posted returns of -18.18% and 12.50% over the past six months, three months period respectively. It had a 52-week high price of $0.009 and touched 52 weeks low of $0.004, with an average volume of ~ 629,726.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK